ğŸ‘ å°åˆ†å­|é‡‘åˆšçƒ·ç±»ä¼¼ç‰©é¶å‘ACE2ç¡«äºšç¡åŸºåŒ–ä»è€ŒæŠ‘åˆ¶æ–°å† ç—…æ¯’æ„ŸæŸ“

---
[TOC]

---
[PPTæ±‡æ€»æ€»ç»“](./å°åˆ†å­é‡‘åˆšçƒ·ç±»ä¼¼ç‰©é¶å‘ACE2ç¡«äºšç¡åŸºåŒ–ä»è€ŒæŠ‘åˆ¶æ–°å† ç—…æ¯’æ„ŸæŸ“/JournalClub_NMT-20221005-yqyang.pptx)

## å‚è€ƒæ–‡çŒ®
* Oh, Ck., Nakamura, T., Beutler, N. et al. Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection. Nat Chem Biol (2022). https://doi.org/10.1038/s41589-022-01149-6 [é‡‘åˆšçƒ·ç¡åŒ–ç‰©åŒæœºåˆ¶é¶å‘ACE2æŠ‘åˆ¶æ–°å† æ„ŸæŸ“æ–‡çŒ®pdf](./å°åˆ†å­é‡‘åˆšçƒ·ç±»ä¼¼ç‰©é¶å‘ACE2ç¡«äºšç¡åŸºåŒ–ä»è€ŒæŠ‘åˆ¶æ–°å† ç—…æ¯’æ„ŸæŸ“/s41589-022-01149-6.pdf)
* Takahashi H, Xia P, Cui J, et al. Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease. Sci Rep. 2015 Oct 19;5:14781. doi: 10.1038/srep14781. [é‡‘åˆšçƒ·ç¡åŒ–ç‰©åŒæœºåˆ¶é¶å‘NMDARæ²»ç–—è„‘è¡€ç®¡ç–¾ç—…æ–‡çŒ®pdf](./å°åˆ†å­é‡‘åˆšçƒ·ç±»ä¼¼ç‰©é¶å‘ACE2ç¡«äºšç¡åŸºåŒ–ä»è€ŒæŠ‘åˆ¶æ–°å† ç—…æ¯’æ„ŸæŸ“/srep14781.pdf)
* Marino SM, Gladyshev VN. Structural analysis of cysteine S-nitrosylation: a modified acid-based motif and the emerging role of trans-nitrosylation. J Mol Biol. 2010 Jan 29;395(4):844-59. doi: 10.1016/j.jmb.2009.10.042. [æ–‡çŒ®pdf](./å°åˆ†å­é‡‘åˆšçƒ·ç±»ä¼¼ç‰©é¶å‘ACE2ç¡«äºšç¡åŸºåŒ–ä»è€ŒæŠ‘åˆ¶æ–°å† ç—…æ¯’æ„ŸæŸ“/1-s2.0-S0022283609012911-main.pdf)
* Kovacs I, Lindermayr C. Nitric oxide-based protein modification: formation and site-specificity of protein S-nitrosylation. Front Plant Sci. 2013 May 14;4:137. doi: 10.3389/fpls.2013.00137. [è›‹ç™½S-äºšç¡åŸºåŒ–çš„å½¢æˆæ–‡ç« pdf](./å°åˆ†å­é‡‘åˆšçƒ·ç±»ä¼¼ç‰©é¶å‘ACE2ç¡«äºšç¡åŸºåŒ–ä»è€ŒæŠ‘åˆ¶æ–°å† ç—…æ¯’æ„ŸæŸ“/fpls-04-00137.pdf)
* Stomberski CT, Hess DT, Stamler JS. Protein S-Nitrosylation: Determinants of Specificity and Enzymatic Regulation of S-Nitrosothiol-Based Signaling. Antioxid Redox Signal. 2019 Apr 1;30(10):1331-1351. doi: 10.1089/ars.2017.7403. [ä¿¡å·è½¬å¯¼ä¸­çš„è›‹ç™½ç¡«äºšç¡åŸºåŒ–ç»¼è¿°æ–‡ç« pdf](./å°åˆ†å­é‡‘åˆšçƒ·ç±»ä¼¼ç‰©é¶å‘ACE2ç¡«äºšç¡åŸºåŒ–ä»è€ŒæŠ‘åˆ¶æ–°å† ç—…æ¯’æ„ŸæŸ“/ars.2017.7403.pdf)
* Cao Y, Yang R, Lee I, Zhang W, Sun J, Wang W, Meng X. Characterization of the SARS-CoV-2 E Protein: Sequence, Structure, Viroporin, and Inhibitors. Protein Sci. 2021 Jun;30(6):1114-1130. doi: 10.1002/pro.4075. [SARS2çš„Eè›‹ç™½ç»¼è¿°æ–‡ç« pdf](./å°åˆ†å­é‡‘åˆšçƒ·ç±»ä¼¼ç‰©é¶å‘ACE2ç¡«äºšç¡åŸºåŒ–ä»è€ŒæŠ‘åˆ¶æ–°å† ç—…æ¯’æ„ŸæŸ“/Protein_Science-2021-Cao-Characterization_of_the_SARS%E2%80%90CoV%E2%80%902_E_Protein_Sequence_Structure_Viroporin_and_Inhibitors.pdf)
* Singh Tomar PP, Arkin IT. SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine. Biochem Biophys Res Commun. 2020 Sep 10;530(1):10-14. doi: 10.1016/j.bbrc.2020.05.206. [SARS2çš„Eè›‹ç™½æ˜¯ä¸€ä¸ªç¦»å­é€šé“è›‹ç™½å¹¶ä¸”å¯è¢«ç¾é‡‘åˆšæŠ‘åˆ¶](./å°åˆ†å­é‡‘åˆšçƒ·ç±»ä¼¼ç‰©é¶å‘ACE2ç¡«äºšç¡åŸºåŒ–ä»è€ŒæŠ‘åˆ¶æ–°å† ç—…æ¯’æ„ŸæŸ“/1-s2.0-S0006291X20311530-main.pdf)
* Mandala VS, McKay MJ, Shcherbakov AA, et al. Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers. Nat Struct Mol Biol. 2020 Dec;27(12):1202-1208. doi: 10.1038/s41594-020-00536-8. [SARS2çš„Eè›‹ç™½NMRç»“æ„](./å°åˆ†å­é‡‘åˆšçƒ·ç±»ä¼¼ç‰©é¶å‘ACE2ç¡«äºšç¡åŸºåŒ–ä»è€ŒæŠ‘åˆ¶æ–°å† ç—…æ¯’æ„ŸæŸ“/s41594-020-00536-8.pdf)
* Lipton SA. Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci. 1993 Dec;16(12):527-32. doi: 10.1016/0166-2236(93)90198-u. [NMDAæ‹®æŠ—å‰‚çš„å¯ç»“åˆä½ç‚¹åˆ†ç±»æ–‡ç« pdf](./å°åˆ†å­é‡‘åˆšçƒ·ç±»ä¼¼ç‰©é¶å‘ACE2ç¡«äºšç¡åŸºåŒ–ä»è€ŒæŠ‘åˆ¶æ–°å† ç—…æ¯’æ„ŸæŸ“/lipton1993.pdf)
* Aizenman E, Lipton SA, Loring RH. Selective modulation of NMDA responses by reduction and oxidation. Neuron. 1989 Mar;2(3):1257-63. doi: 10.1016/0896-6273(89)90310-3. [æœ€æ—©å‘ç°æ°§åŒ–è¿˜åŸååº”å¯¹NMDAå½±å“çš„æ–‡ç« pdf](./å°åˆ†å­é‡‘åˆšçƒ·ç±»ä¼¼ç‰©é¶å‘ACE2ç¡«äºšç¡åŸºåŒ–ä»è€ŒæŠ‘åˆ¶æ–°å† ç—…æ¯’æ„ŸæŸ“/aizenman1989.pdf)
* AÌŠkerstroÌˆm S, Mousavi-Jazi M, KlingstroÌˆm J, et al. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus[J]. Journal of virology, 2005, 79(3): 1966-1969. [NOæŠ‘åˆ¶SARSçš„æ–‡ç« pdf](./å°åˆ†å­é‡‘åˆšçƒ·ç±»ä¼¼ç‰©é¶å‘ACE2ç¡«äºšç¡åŸºåŒ–ä»è€ŒæŠ‘åˆ¶æ–°å† ç—…æ¯’æ„ŸæŸ“/JVI.79.3.1966-1969.2005.pdf)
* AkerstrÃ¶m S, Gunalan V, Keng CT, Tan YJ, Mirazimi A. Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected. Virology. 2009 Dec 5;395(1):1-9. doi: 10.1016/j.virol.2009.09.007. [NOæŠ‘åˆ¶SARSå¤åˆ¶å¹¶ä¸”å½±å“S-ACE2ç»“åˆçš„æ–‡ç« pdf](./å°åˆ†å­é‡‘åˆšçƒ·ç±»ä¼¼ç‰©é¶å‘ACE2ç¡«äºšç¡åŸºåŒ–ä»è€ŒæŠ‘åˆ¶æ–°å† ç—…æ¯’æ„ŸæŸ“/1-s2.0-S0042682209005558-main.pdf)
* Barros EP, Casalino L, Gaieb Z, Dommer AC, Wang Y, Fallon L, Raguette L, Belfon K, Simmerling C, Amaro RE. The flexibility of ACE2 in the context of SARS-CoV-2 infection. Biophys J. 2021 Mar 16;120(6):1072-1084. doi: 10.1016/j.bpj.2020.10.036. [è®¡ç®—æ¨¡æ‹Ÿè¯æ˜ACE2äºŒèšåŒ–æ›´æœ‰åŠ©äºä¸Spikeçš„ç»“åˆæ–‡ç« pdf](./å°åˆ†å­é‡‘åˆšçƒ·ç±»ä¼¼ç‰©é¶å‘ACE2ç¡«äºšç¡åŸºåŒ–ä»è€ŒæŠ‘åˆ¶æ–°å† ç—…æ¯’æ„ŸæŸ“/The_flexibility_of_ACE2_in_the_context_of_SARS-CoV-2.pdf)
* [NMDAå—ä½“ç›¸å…³ç®€ä»‹](http://wiki.bioguider.com/doc-view-8297.html)